Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer

被引：0
|
作者：
Green Hong
Pureum Sun
Chaeuk Chung
Dongil Park
Song-I Lee
Nayoung Kim
Seong Eun Lee
Jeong Eun Lee
Yea Eun Kang
Da Hyun Kang
机构：
[1] Chungnam National University,Department of Internal Medicine, College of Medicine
[2] Chungnam National University,Institute for Medical Sciences, College of Medicine
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
GDF15; Non-small cell lung cancer; Immunotherapy; Survival; Biomarker; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：159 / 171
页数：12
相关论文
共 50 条
  • [31] Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
    Luo, Fan
    Luo, Min
    Rong, Qi-Xiang
    Zhang, Hong
    Chen, Zhen
    Wang, Fang
    Zhao, Hong-Yun
    Fu, Li-Wu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [32] The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
    Qian Zhu
    Hao Hu
    Li-Ying OuYang
    Rong Yang
    Wen-Xiao Wei
    Pin Huang
    Xin-Rong He
    BMC Cancer, 25 (1)
  • [33] Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
    Wang, Xueping
    Guo, Zhixing
    Wu, Xingping
    Chen, Da
    Wang, Fang
    Yang, Lewei
    Luo, Min
    Wu, Shaocong
    Yang, Chuan
    Huang, Lamei
    Fu, Liwu
    IMMUNOTARGETS AND THERAPY, 2023, 12 : 1 - 16
  • [34] Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials
    Peng, Tzu-Rong
    Wu, Ta-Wei
    THORACIC CANCER, 2019, 10 (05) : 1176 - 1181
  • [35] The predict factors and clinical prognosis value of immune-related pneumonia of receiving PD-1 inhibitor in advanced non-small cell lung cancer: A retrospective study
    Yang, Jin
    Lyu, Mengchen
    Feng, Xiangran
    Liu, Fang
    Zeng, Ran
    Sun, Xianwen
    Bao, Zhiyao
    Zhou, Ling
    Gao, Beli
    Ni, Lei
    Xiang, Yi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 142
  • [36] Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
    Li, Xiang
    Yan, Shi
    Yang, Jichun
    Wang, Yaqi
    Lv, Chao
    Li, Shaolei
    Zhao, Jun
    Yang, Yue
    Zhuo, Minglei
    Wu, Nan
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [37] Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China
    Sheng, Jiamin
    Li, Hui
    Yu, Xiaoqing
    Yu, Sizhe
    Chen, Kaiyan
    Pan, Guoqiang
    Xie, Mingying
    Li, Na
    Zhou, Zichao
    Fan, Yun
    THORACIC CANCER, 2021, 12 (22) : 3019 - 3031
  • [38] Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer
    Sun, Yuxin
    Shao, Chi
    Li, Shan
    Xu, Yan
    Xu, Kai
    Zhang, Ying
    Huang, Hui
    Wang, Mengzhao
    Xu, Zuojun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 299 - 304
  • [39] Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
    Sakamoto, Mandy
    Jimeno, Antonio
    DRUGS OF TODAY, 2023, 59 (03) : 169 - 177
  • [40] PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
    Moradi, Samaneh
    Sarikhani, Pedram
    Albadr, Rafid Jihad
    Taher, Waam Mohammed
    Alwan, Mariem
    Jawad, Mahmood Jasem
    Mushtaq, Hiba
    Vakilzadehian, Niyousha
    DISCOVER ONCOLOGY, 2025, 16 (01)
12345